Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased securities of Jayud Global Logistics Ltd. during the specified Class Period, highlighting potential compensation opportunities for affected investors [2][3]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between April 21, 2023, and April 30, 2025, and investors must act by January 20, 2026, to serve as lead plaintiff [2][4]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. Group 2: Allegations Against Jayud - The lawsuit alleges that Jayud made materially false and misleading statements, failed to disclose involvement in a fraudulent stock promotion scheme, and omitted critical information regarding stock price manipulation [6]. - Specific allegations include the use of offshore accounts for coordinated share dumping and misleading public statements about the company's business and operations [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [5].

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for allegedly misleading investors regarding its financial health and operations during the period from February 27, 2023, to November 4, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Perrigo made materially false and misleading statements about its infant formula business acquired from Nestlé, which suffered from significant underinvestment and required substantial capital expenditures [5]. - It is alleged that there were significant manufacturing deficiencies in Perrigo's infant formula facility, leading to overstated financial results, including earnings and cash flow [5]. - The lawsuit asserts that the positive statements made by Perrigo regarding its business and prospects were materially misleading and lacked a reasonable basis [5]. Group 2: Investor Information - Investors who purchased Perrigo securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm for more information [3][6]. - A lead plaintiff must be appointed by January 16, 2026, to represent the interests of other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Points - Rosen Law Firm is reminding investors of Primo Brands Corporation and Primo Water Corporation about the upcoming lead plaintiff deadline for a securities class action lawsuit, which is set for January 12, 2026 [2][4] Group 1: Class Action Details - The class period for the lawsuit includes purchasers of Primo Water Corporation common stock from June 17, 2024, to November 8, 2024, and purchasers of Primo Brands Corporation common stock from November 11, 2024, to November 6, 2025 [2][6] - Investors who purchased securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][4] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5] - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [5] Group 3: Case Background - The lawsuit claims that Primo Brands, formed after the merger between Primo Water and BlueTriton Brands, misrepresented key facts about the merger, leading investors to believe in accelerated growth and strong financial results [6] - The defendants allegedly issued materially false and misleading statements regarding the merger integration, which ultimately caused investor damages when the true details were revealed [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [2][4]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 5, 2026 [4][6]. - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary steps for its launch, leading to investor damages when the truth was revealed [6]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [5]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements since 2013 [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Performance and Stock Impact - On August 4, 2025, Agilon Health reported its second quarter results, indicating that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [3]. - Following this announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 2: Legal Actions and Investor Rights - Shareholders who purchased Agilon Health securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the alleged misleading information [2]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a securities class action related to alleged misleading statements and health risks associated with the company's glucose monitoring systems [2][3][6]. Group 1: Class Action Details - The class action pertains to investors who purchased DexCom securities between July 26, 2024, and September 17, 2025 [2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A lead plaintiff must file a motion with the court by December 29, 2025, to represent other class members [4]. Group 2: Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [6]. - Defendants allegedly overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues [6]. - The situation has led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [5]. - The firm was ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [5]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Stride, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who purchased Stride securities between October 22, 2024, and October 28, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 12, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Stride made misleading statements about its products and services, inflating enrollment numbers and cutting staff costs beyond statutory limits [5]. - The firm claims that when the true details about Stride's operations became known, investors suffered damages [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of CarMax, Inc. to secure legal counsel before the January 2, 2026 deadline for a securities class action lawsuit related to the company's misleading statements during the class period from June 20, 2025, to November 5, 2025 [2][6]. Summary by Sections Class Action Details - Investors who purchased CarMax securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 2, 2026 [4]. Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering hundreds of millions for investors [5]. - The firm has been recognized for its leadership in securities class action settlements, achieving significant recoveries in previous years [5]. Allegations Against CarMax - The lawsuit alleges that CarMax's management made materially false and misleading statements regarding the company's growth prospects, which were overstated due to temporary market conditions [6]. - The claims suggest that when the true nature of the company's performance became known, investors suffered damages as a result of these misleading statements [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Synopsys, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Synopsys securities between December 4, 2024, and September 9, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 30, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Synopsys made materially false and misleading statements and failed to disclose adverse facts about its business and operations during the Class Period [5]. - Specific claims include that Synopsys' focus on artificial intelligence customers negatively impacted the economics of its Design IP business and that certain strategic decisions were unlikely to yield intended results [5]. - The lawsuit asserts that these undisclosed issues had a materially negative impact on Synopsys' financial results, leading to investor damages when the true information became public [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased securities of Perrigo Company plc during the specified Class Period, highlighting the importance of securing legal counsel before the upcoming deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between February 27, 2023, and November 4, 2025, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - Investors wishing to serve as lead plaintiff must file their motion by January 16, 2026, and a lead plaintiff acts on behalf of other class members in directing the litigation [1][3]. Group 2: Allegations Against Perrigo - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business acquired from Nestlé, which suffered from significant underinvestment and required substantial capital expenditures beyond stated estimates [5]. - It is claimed that there were significant manufacturing deficiencies in Perrigo's infant formula facility, leading to overstated financial results, including earnings and cash flow, and that positive statements about the company's business were materially misleading [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, noting its history of achieving significant settlements for investors, including over $438 million in 2019 alone [4]. - The firm has been recognized for its leadership in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 and consistently in the top 4 since 2013 [4].